Japanese initiative on unapproved products bearing fruit
This article was originally published in Scrip
Japan's effort to improve the availability of drugs for unmet medical needs appears to be paying dividends, with a number of products for serious disorders recently approved or submitted for regulatory review as part of the ongoing government initiative. The developments have come across a wide range of therapeutic areas from oncology through cardiovascular to infections, reflecting the numerous gaps in the availability of common treatments that have been identified under the programme.
You may also be interested in...
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.